Evolution of fit-for-purpose biomarker validations: an LBA perspective
Related Experiment Video
Updated: Feb 8, 2026

Daily Transfers, Archiving Populations, and Measuring Fitness in the Long-Term Evolution Experiment with Escherichia coli
Published on: August 18, 2023
1Senior Research Investigator, Bioanalytical Sciences - Biomarkers, Bristol-Myers Squibb, Route 206 & Province Line Road, Princeton, NJ 08543-4000, USA.
Abstract:
Biomarker ligand-binding assays need to be validated for use on clinical studies in the drug development process. There is not one single guidance to cover all types of biomarker assays and their intended uses. Therefore, it is up to the scientist to piece together a validation strategy based on published papers and other sources. Shown here is a summary of what to take into consideration during a validation and how to apply it for use in the drug development process.
More Related Videos
09:00High Throughput Sequential ELISA for Validation of Biomarkers of Acute Graft-Versus-Host Disease
Published on: October 31, 2012
05:51Assessing the Accuracy of Fitness Smartwatch Data for Cardiovascular and Physical Activity Monitoring: A Validation Study in Digital Health
Published on: February 21, 2025
Related Concept Videos
The Evidence for Evolution
Convergent Evolution
Induced-fit Model
Enzymes exhibit substrate specificity, meaning that they can only bind to certain substrates. This is mainly determined by the shape and chemical...
Purposive Learning
Reliability and Validity
Inclusive Fitness